https://prabadinews.com/
  • October 9, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

Zanubrutinib Outperforms Acalabrutinib in Adjusted Head-to-Head Analysis

Zanubrutinib Outperforms Acalabrutinib in Adjusted Head-to-Head Analysis

An adjusted analysis of the ALPINE and ASCEND trials revealed a statistically significant progression-free survival advantage for Zanubrutinib.

administrator

Related Articles